NASDAQ$AMPH
Amphastar Pharmaceuticals Inc · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Amphastar Pharmaceuticals reported financial results for the three months and full year ended December 31, 2024, with increased net revenues and net income for both periods.
Amphastar Pharmaceuticals reported strong financial results for the fourth quarter of 2024, with net revenues increasing to $186.5 million and GAAP net income reaching $38.0 million. The company also exceeded its long-term goal for Primatene MIST® annual sales and saw significant growth in BAQSIMI® factory sales.
- Net revenues for Q4 2024 increased to $186.5 million, up from $178.1 million in Q4 2023.
- GAAP net income for Q4 2024 was $38.0 million, or $0.74 per diluted share.
- Adjusted non-GAAP net income for Q4 2024 was $47.2 million, or $0.92 per diluted share.
- Primatene MIST® sales increased by 18% in Q4 2024, and BAQSIMI® sales contributed significantly to product revenues.
Headline financials
Revenue & EPS history
Amphastar · Revenue · Quarterly
$187M
Revenue by segment
Amphastar · $90.1M total across 4 segments · Q3 2023
- Glucagon$29.5M+107.5%32.8%
- Primatene MIST®$24.8M+35.3%27.6%
- Epinephrine$20.2M+3.6%22.4%
- Lidocaine$15.5M+23.0%17.2%
Forward guidance
Amphastar Pharmaceuticals anticipates continued growth in its proprietary pipeline and brands like Primatene MIST® and BAQSIMI® in 2025.
Tailwinds
- Exceeded long-term goal of achieving $100 million in annual sales for Primatene MIST® in 2024.
- BAQSIMI® showed strong factory sales growth of 12% compared to the fourth quarter of last year.
- Plans to continue developing and growing the proprietary pipeline in 2025.
- Company has four ANDAs filed with the U.S. FDA targeting products with a market size exceeding $2 billion.
- Company is developing multiple proprietary products with injectable and intranasal dosage forms.
Headwinds
- Glucagon sales decreased due to competition and a market shift towards ready-to-use products.
- Epinephrine sales decreased due to new competition for the epinephrine vial product.
- Sales of phytonadione and naloxone decreased due to lower unit volumes and average selling prices.
- Enoxaparin sales decreased primarily due to a decrease in unit volumes.
- Other revenues decreased as the Transition Service Agreement with Lilly expired, shifting BAQSIMI® sales to product revenues.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
+0.4%
Avg return
Earnings day
-1.1%
Avg return
5 days after
+1.3%
Avg return
30 days after
52%
27 / 52 earnings
Positive
+14.3%
Q3 2016
Best reaction
-23.8%
Q1 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.4% | -26.8% | -17.4% | |
| Q4 2025 | -23.5% | -24.7% | -28.2% | |
| Q3 2025 | -4.4% | +7.3% | +5.8% | |
| Q1 2025 | +0.9% | -2.3% | +6.4% | |
| Q4 2024 | -9.7% | -10.9% | -9.7% | |
| Q3 2024 | -10.6% | -5.8% | -15.1% | |
| Q2 2024 | +11.8% | +9.8% | +15.2% | |
| Q1 2024 | -0.8% | -0.9% | -4.8% | |
| Q4 2023 | -16.0% | -15.8% | -20.8% | |
| Q3 2023 | +13.9% | +16.4% | +23.4% | |
| Q2 2023 | -1.4% | -13.3% | -18.8% | |
| Q1 2023 | +13.1% | +14.3% | +26.0% | |
| Q4 2022 | +12.6% | +11.2% | +16.1% | |
| Q3 2022 | -8.3% | -4.9% | -0.9% | |
| Q2 2022 | -12.8% | -14.0% | -22.6% | |
| Q1 2022 | +3.9% | +8.0% | +17.1% | |
| Q4 2021 | +14.0% | +15.4% | +36.7% | |
| Q3 2021 | +3.4% | +6.1% | +6.0% | |
| Q2 2021 | +0.0% | -3.5% | -7.8% | |
| Q1 2021 | +4.1% | +5.7% | +4.7% | |
| Q4 2020 | -4.8% | -6.7% | -10.1% | |
| Q3 2020 | -7.9% | -5.3% | -8.1% | |
| Q2 2020 | -4.5% | -5.7% | -5.5% | |
| Q1 2020 | +8.4% | +6.9% | +12.6% | |
| Q4 2019 | -7.3% | -5.2% | +7.6% | |
| Q3 2019 | -3.5% | -7.6% | -0.8% | |
| Q2 2019 | +7.7% | +5.5% | +10.5% | |
| Q1 2019 | -0.4% | -6.7% | -10.7% | |
| Q4 2018 | -12.8% | -14.7% | -11.6% | |
| Q3 2018 | +12.2% | +10.2% | +14.2% | |
| Q2 2018 | -3.5% | -1.0% | +8.3% | |
| Q1 2018 | -23.8% | -16.1% | -13.2% | |
| Q4 2017 | +6.3% | +4.0% | +0.4% | |
| Q3 2017 | +5.1% | -0.2% | +3.2% | |
| Q2 2017 | -2.4% | -5.6% | +0.3% | |
| Q1 2017 | -1.8% | +8.1% | +13.0% | |
| Q4 2016 | -16.6% | -6.0% | +1.0% | |
| Q3 2016 | +14.3% | +16.6% | +11.2% | |
| Q2 2016 | +12.4% | +13.3% | +19.2% | |
| Q1 2016 | +10.8% | — | — | |
| Q4 2015 | +11.9% | — | — | |
| Q3 2015 | +10.7% | — | — | |
| Q2 2015 | -2.6% | — | — | |
| Q1 2014 | +0.4% | — | — | |
| Q1 2015 | +7.0% | — | — | |
| Q4 2012 | +7.0% | — | — | |
| Q1 2013 | +7.0% | — | — | |
| Q4 2014 | -6.1% | — | — | |
| Q3 2014 | +7.0% | — | — | |
| Q2 2013 | -0.7% | — | — | |
| Q4 2013 | -0.7% | — | — | |
| Q2 2014 | +1.5% | — | — | |
| Q3 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro